STOCK TITAN
  1. Home
  2. Sec-filings
  3. NVCR
  4. [Form 4] NovoCure Ltd Insider Trading Activity

NovoCure (NVCR) grants RSUs and stock options to director Scannell

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

NovoCure Ltd director Timothy J. Scannell received new equity awards as part of his compensation. On June 3, 2026, he was granted 11,610 restricted stock units and stock options for 16,999 ordinary shares at an exercise price of $16.15 per share.

The restricted stock units and options are scheduled to vest 100% on the earlier of the first anniversary of the grant date or the day immediately preceding NovoCure’s 2027 annual general meeting of shareholders. After the restricted stock unit grant, Scannell directly holds 25,898 ordinary shares.

Positive

  • None.

Negative

  • None.
Insider Scannell Timothy J
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 16,999 $0.00 --
Grant/Award Ordinary Shares 11,610 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 16,999 shares (Direct, null); Ordinary Shares — 25,898 shares (Direct, null)
Footnotes (1)
  1. Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders. Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.
Restricted stock units granted 11,610 shares RSU grant on June 3, 2026
Options granted 16,999 shares Stock Option (Right to Buy) on June 3, 2026
Option exercise price $16.15 per share Conversion/exercise price for 16,999 options
Shares held after RSU grant 25,898 shares Direct ordinary share holdings after acquisition
Option vesting trigger 1-year anniversary or pre-2027 AGM Full vesting condition for stock options
Option expiration June 3, 2036 Expiry date of 16,999 stock options
restricted stock units financial
"Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with 16,999.0000 shares and a $16.1500 exercise price"
annual general meeting of shareholders financial
"the day immediately preceding the Company's 2027 annual general meeting of shareholders"
exercise price financial
"conversion_or_exercise_price: "16.1500" for the stock options"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Scannell Timothy J
(Last)(First)(Middle)
C/O NOVOCURE INC.
1550 LIBERTY RIDGE DRIVE, SUITE 115
(Street)
WAYNE PENNSYLVANIA 19087
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
NovoCure Ltd [ NVCR ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Ordinary Shares(1)06/03/2026A11,610A$0.0025,898D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$16.1506/03/2026A16,99906/03/2027(2)06/03/2036Ordinary Shares16,999$0.0016,999D
Explanation of Responses:
1. Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.
2. Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.
Remarks:
Steven Robbins, as attorney in fact for Scannell, Timothy J.06/05/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What equity awards did NovoCure (NVCR) director Timothy J. Scannell receive?

Timothy J. Scannell received 11,610 restricted stock units and stock options on 16,999 ordinary shares. The options carry a $16.15 exercise price. Both awards represent compensation-related grants rather than open-market purchases or sales, aligning his interests more closely with NovoCure shareholders.

When do Timothy J. Scannell’s NovoCure (NVCR) restricted stock units vest?

The 11,610 restricted stock units vest 100% on a single future date. Vesting occurs on the earlier of the first anniversary of the June 3, 2026 grant date or the day immediately preceding NovoCure’s 2027 annual general meeting of shareholders, creating a clear time-linked incentive.

What are the terms of Timothy J. Scannell’s NovoCure (NVCR) stock options?

Scannell received options on 16,999 ordinary shares at a $16.15 exercise price. These options fully vest and become exercisable on the earlier of the first anniversary of the June 3, 2026 grant date or the day immediately preceding NovoCure’s 2027 annual general meeting, and expire on June 3, 2036.

How many NovoCure (NVCR) shares does Timothy J. Scannell hold after these grants?

Following the 11,610 restricted stock unit grant, Scannell directly holds 25,898 ordinary shares. This figure reflects his direct non-derivative holdings reported in the filing and does not include the 16,999 underlying shares tied to his newly granted stock options.

Are Timothy J. Scannell’s NovoCure (NVCR) transactions open-market buys or compensation grants?

The transactions are compensation-related grants, not open-market trades. Both the 11,610 restricted stock units and 16,999 stock options are coded as awards, with a zero-dollar grant price, indicating they were issued by NovoCure as part of director compensation rather than purchased in the market.